Phase 2 Study in Vascular Inflammation on Patients After an Acute Coronary Syndrome Event
Conditions
Interventions
- DRUG: VIA-2291
- DRUG: Placebo
Sponsor
Tallikut Pharmaceuticals, Inc.
Collaborators
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]